183 related articles for article (PubMed ID: 36530970)
21. Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis.
Hassen G; Kasar A; Jain N; Berry S; Dave J; Zouetr M; Priyanka Ganapathiraju VLN; Kurapati T; Oshai S; Saad M; Pathan J; Kamat S; Tirupathi R; Patel UK; Rana RK
Cureus; 2022 Apr; 14(4):e23845. PubMed ID: 35530821
[TBL] [Abstract][Full Text] [Related]
22. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
Front Oncol; 2019; 9():897. PubMed ID: 31620360
[No Abstract] [Full Text] [Related]
23. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
24. Tryptophan 2,3-dioxygenase may be a potential prognostic biomarker and immunotherapy target in cancer: A meta-analysis and bioinformatics analysis.
Hu Y; Liu Z; Tang H
Front Oncol; 2022; 12():977640. PubMed ID: 36263228
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
26. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.
Li H; Xu Y; Wan B; Song Y; Zhan P; Hu Y; Zhang Q; Zhang F; Liu H; Li T; Sugimura H; Cappuzzo F; Lin D; Lv T;
Transl Lung Cancer Res; 2019 Aug; 8(4):429-449. PubMed ID: 31555517
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis.
Lee W; Kim MJ; Choi Y; Kim H
Transl Cancer Res; 2021 May; 10(5):2210-2218. PubMed ID: 35116539
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
30. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.
Wang S; Yuan B; Wang Y; Li M; Liu X; Cao J; Li C; Hu J
Int J Colorectal Dis; 2021 Jan; 36(1):117-130. PubMed ID: 32910207
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.
Xu F; Xu L; Wang Q; An G; Feng G; Liu F
Int J Clin Exp Med; 2015; 8(9):14595-603. PubMed ID: 26628942
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Huang W; Ran R; Shao B; Li H
Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
[TBL] [Abstract][Full Text] [Related]
35. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with sarcomatoid dedifferentiation: A PRISMA-compliant systematic review and meta-analysis.
Shan L; Shao X; Gu L; Wu M; Lin P; Yu Z; Chen Q; Zhu D
Front Surg; 2022; 9():922150. PubMed ID: 36338616
[TBL] [Abstract][Full Text] [Related]
37. Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status.
Ottenhof SR; Djajadiningrat RS; de Jong J; Thygesen HH; Horenblas S; Jordanova ES
J Urol; 2017 Mar; 197(3 Pt 1):690-697. PubMed ID: 27697578
[TBL] [Abstract][Full Text] [Related]
38. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Cai H; Zhang H; Jiang Y
Front Oncol; 2020; 10():1079. PubMed ID: 32670887
[No Abstract] [Full Text] [Related]
40. Prognostic value of
Ling T; Zhang L; Peng R; Yue C; Huang L
Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
